A feasibility study conducted by Wacker Biotech GmbH on behalf of MorphoSys AG using Fab fragments, demonstrated that WACKER’s E. coli secretion system can offer a far simpler and more cost-effective way of obtaining high yields of antibody fragments, which are used for research, diagnostic and therapeutic applications.